Anzeige
Mehr »
Samstag, 19.07.2025 - Börsentäglich über 12.000 News
Kupfer en mass...: 10 Prozent-Kupfer an der Oberfläche! - Diese Entdeckung könnte zur heißesten Kupferstory des Jahres werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MF2 | ISIN: US7574683014 | Ticker-Symbol: 2RH
NASDAQ
18.07.25 | 21:25
1,930 US-Dollar
-20,25 % -0,490
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REDHILL BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
REDHILL BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur REDHILL BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.07.RedHill Biopharma Ltd.: RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer211Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...
► Artikel lesen
25.06.RedHill Biopharma Ltd. - F-1, Registration statement for certain foreign private issuers10
25.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
27.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer22
REDHILL BIOPHARMA Aktie jetzt für 0€ handeln
13.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
05.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
28.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer12
17.04.RedHill Biopharma steht vor Compliance-Problemen mit der NASDAQ37
17.04.RedHill Biopharma faces Nasdaq non-compliance issue3
17.04.RedHill Biopharma receives Nasdaq letter over minimum stockholders' equity deficiency2
17.04.RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency195The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected...
► Artikel lesen
16.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer2
10.04.RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights686Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: ...
► Artikel lesen
10.04.RedHill Biopharma Ltd. - 20-F, Annual and transition report of foreign private issuers3
08.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer10
26.03.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
25.03.RedHill Biopharma Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
18.03.RedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation621RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK...
► Artikel lesen
12.03.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer8
25.02.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer17
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3